Abbott Laboratories (ABT.US) fell more than 7% in pre-market trading on Thursday, to $112.02. The company reported fourth-quarter 2025 sales of $114.6 billion, missing expectations by $340 million, representing a 4.4% increase on a reported basis and 3.8% organic growth excluding the impact of COVID-19 testing.

Adjusted earnings per share (EPS) for the fourth quarter reached $1.50, a 12% year-over-year increase, while full-year 2025 adjusted EPS grew 10% to $5.15. The company's Medical Devices division led the growth, surging 12.3%, primarily driven by strong performance in Diabetes Care and Electrophysiology.

For the full year 2025, the company achieved sales of $44.3 billion, a 5.7% increase on a reported basis. Sales from the continuous glucose monitoring business reached $2.0 billion in the fourth quarter, growing 15.0% on a reported basis.

Looking ahead, the company forecasts full-year 2026 organic sales growth of 6.5% to 7.5%, with adjusted EPS projected to be between $5.55 and $5.80, representing a 10% increase at the midpoint. The company expects to complete its strategic acquisition of Exact Sciences in the second quarter of 2026, marking its entry into the rapidly growing cancer diagnostics market.